Scalper1 News
Big pharma Eli Lilly (LLY) said Wednesday that its drug candidate ramucirumab improved the survival of lung-cancer patients in a late-stage study. Lilly stock gapped up 3% in early trading on the stock market today. The study looked at patients with metastatics non-small-cell lung cancer (NSCLC) who had failed a previous round of platinum-based chemotherapy. One group of patients took standard cancer drug docetaxel (best known as Sanofi’s (SNY) Scalper1 News
Scalper1 News